Insider Buying: Keros Therapeutics, Inc. (NASDAQ:KROS) Major Shareholder Acquires 934,258 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Keros Therapeutics Trading Down 0.5 %

Shares of KROS opened at $12.18 on Monday. The firm has a market cap of $494.05 million, a price-to-earnings ratio of -2.34 and a beta of 1.39. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37. The stock has a 50 day moving average of $10.91 and a 200-day moving average of $30.62.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. On average, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Cantor Fitzgerald cut shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Wells Fargo & Company dropped their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Oppenheimer reduced their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Finally, Truist Financial dropped their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. AlphaQuest LLC lifted its holdings in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC raised its position in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Keros Therapeutics in the 4th quarter worth approximately $90,000. Exchange Traded Concepts LLC acquired a new position in Keros Therapeutics during the 4th quarter valued at approximately $99,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in Keros Therapeutics by 207.8% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after buying an additional 4,976 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.